Get started
Author

A. Piedra

Observed names: A. Piedra Cascon, A. Piedra-Cascon, Aida Piedra Cascon, Aida Piedra, Aida Piedra Cascon, Aida Piedra Cascón, Piedra, Aida
ORCID: 0000-0002-4795-1132
Observed ORCID: 0000-0002-4795-1132
OpenAlex ID: A5062276540
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
2021 · A. Cortellini, B. Ricciuti, et al. · Annals of Oncology · 67
PDF
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
2023 · Talal El Zarif, Amin H Nassar, et al. · JNCI Journal of the National Cancer Institute · 59
PDF
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
2022 · Alessio Cortellini, Biagio Ricciuti, et al. · Journal for ImmunoTherapy of Cancer · 36
PDF
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
2024 · Aida Piedra, Sergio Martínez-Recio, et al. · Frontiers in Oncology · 7
PDF
Capecitabine-Related Thrombotic Microangiopathy
2024 · Francisco J. Pelegrín Mateo, Anna Dominguez Guasch, et al. · Journal of Gastrointestinal Cancer · 5
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
2025 · Alessio Cortellini, Valentina Santo, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2024 · Alessio Cortellini, Edoardo Garbo, et al. · Regular and Young Investigator Award Abstracts · 2
Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
2024 · Miguel Caballero-Borrego, Aida Piedra, et al. · Brazilian Journal of Otorhinolaryngology · 2
Immune phenotype and RAS/BRAF status predict outcomes after lung metastasectomy for colorectal cancer
2026 · Berta Martin-Cullell, Aida Piedra, et al. · Clinical & Translational Oncology · 1
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
2025 · Alessio Cortellini, Edoardo Garbo, et al. · Lung Cancer · 1
PDF
P-278 Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
2023 · A. Romano, J. Gavira, et al. · Annals of Oncology · 1
PDF
Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1
2026 · Albert Guinart-Cuadra, Aida Piedra, et al. · International Journal of Molecular Sciences
Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.
2026 · Mikel Portu, Judit Sanz-Beltran, et al. · Journal of Clinical Oncology
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
2026 · Aida Piedra, Albert Guinart-Cuadra, et al. · Journal of Translational Medicine
PDF
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
2026 · Piedra, Aida, Guinart-Cuadra, Albert, et al. · Figshare
Additional file 1 of Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
2026 · Piedra, Aida, Guinart-Cuadra, Albert, et al. · Figshare
Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
2026 · Piedra, Aida, Guinart Cuadra, Albert, et al. · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
Factores predictivos de eficacia y toxicidad a inmunoterapia en carcinoma microcítico y no microcítico de pulmón
2026 · Piedra, Aida · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
PDF
P1.17.54 Long-Term Outcomes From Pembrolizumab in Patients With Advanced PD-L1 =50% NSCLC and Poor PS: A Transformer-Based AI Approach
2025 · A. Cortellini, E. Garbo, et al. · Journal of Thoracic Oncology
138P Germline pathogenic variants in newly diagnosed sarcomas: Prevalence and implications for clinical and preventive management - Experience of a Spanish National Reference Center
2025 · R. Teres Lleida, M. Aguado Sorolla, et al. · ESMO Open
PDF
319P: Basal PD-L1 expression on leukocyte subpopulations in patients with extensive-stage small cell lung cancer treated with first-line atezolizumab plus platinum and etoposide
2025 · J. Sanz Beltran, A. Guinart-Cuadra, et al. · Journal of Thoracic Oncology
PDF
313P: Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial
2025 · A. Piedra, A. Guinart-Cuadra, et al. · Journal of Thoracic Oncology
P3.13C.03 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC
2024 · A. Piedra, A. Guinart-Cuadra, et al. · Journal of Thoracic Oncology
PDF
1797P Association between baseline PD-L1 expression in circulating leukocytes, the presence of immune-related adverse events (irAEs) and survival outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC) from the CANTABRICO trial
2024 · A. Piedra, A. Guinart-Cuadra, et al. · Annals of Oncology
PDF
122P Immune phenotypes and histological growth patterns in resected lung metastasis of colorectal cancer patients to assess prognosis
2024 · B. Martin Cullell, A.C. Virgili Manrique, et al. · Annals of Oncology
PDF
Works count: 41
Citation count: 183
H-index: 5
I10-index: 3
Year
Topic
Type